Prostate cancer screening—when to start and how to screen?

Prostate-specific antigen (PSA) screening reduces prostate cancer (PCa) mortality; however such screening may lead to harm in terms of overdiagnosis and overtreatment. Therefore, upfront shared decision making involving a discussion about pros and cons between a physician and a patient is crucial. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohestani, Kimia, Chilov, Marina, Carlsson, Sigrid V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861291/
https://www.ncbi.nlm.nih.gov/pubmed/29594018
http://dx.doi.org/10.21037/tau.2017.12.25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861291/
https://www.ncbi.nlm.nih.gov/pubmed/29594018
http://dx.doi.org/10.21037/tau.2017.12.25

Ejemplares similares